丁丙诺啡透皮贴剂用于关节镜下肩袖修复术后镇痛是否比口服药物更有效?一项随机临床试验
这项前瞻性单中心随机对照试验纳入因部分或全层肩袖撕裂(前后向<3 cm)行关节镜下肩袖修复术的患者,比较丁丙诺啡透皮贴剂与口服曲马多联合塞来昔布两种镇痛方案。结果显示两组在各时间点静息或活动时NRS疼痛评分及ASES评分均无临床重要差异,实验组住院期间术后头晕或嗜睡及恶心发生率略低;作者因此不推荐常规使用丁丙诺啡贴剂用于该适应证。
要点
- 两组各时间点静息或活动时NRS评分及ASES评分均无临床重要差异。
- 实验组住院期间术后头晕或嗜睡20%(6/30)低于对照组44%(14/32),P=0.04。
- 实验组恶心10%(3/30)低于对照组34%(11/32),P=0.02。
核心结论
- 该随机试验未发现丁丙诺啡贴剂在关节镜下肩袖修复术后镇痛或功能方面具有临床重要优势。
- 证据不足以确认短暂副作用上的微小差异能否证明在该情境下使用一种新的、大多未经检验的镇痛方法合理。
- 作者不推荐该适应证常规使用丁丙诺啡贴剂。
- 两组术后疼痛水平均较低,未来研究应关注丁丙诺啡贴剂对更具侵入性或更疼痛操作的效果。
研究设计与样本
- 前瞻性、单中心、随机对照试验,证据等级I级(治疗性研究)。
- 纳入经术前MRI评估前后向尺寸<3 cm的部分或全层肩袖撕裂行关节镜下肩袖修复术的患者。
- 排除肥胖、妊娠、阿片依赖、心脏搭桥手术史或同侧肩袖修复史、对试验药物过敏、正在使用抗凝药或抗抑郁药、正在接受其他术后疼痛管理方法或严重肝肾功能不全者。
- 112例患者中64%(72/112)符合条件并随机分为对照组(口服曲马多和塞来昔布)或实验组(丁丙诺啡贴剂),每组36例。
- 对照组术后每12小时口服曲马多100 mg和塞来昔布200 mg,持续2周;实验组术前约48小时使用丁丙诺啡贴剂且不用任何口服药物。
主要发现
- 两组在任何时间点静息或活动时NRS疼痛评分均无临床重要组间差异。
- 两组在任何时间点ASES评分均无临床重要组间差异。
- 住院期间术后头晕或嗜睡实验组20%(6/30)vs对照组44%(14/32),P=0.04。
- 住院期间恶心实验组10%(3/30)vs对照组34%(11/32),P=0.02。
关键数值与推荐
- NRS疼痛评分范围0至10分,0表示无痛,10表示最痛;最小临床重要差异定义为2/10分。
- ASES评分范围0至100分,分数越高肩关节功能越好;最小临床重要差异定义为15/100分。
- 上述最小临床重要差异基于其他研究报告的锚定法确定。
临床怎么用
- 作者不推荐该适应证常规使用丁丙诺啡贴剂。
- 两组术后疼痛水平均较低。
- 未来研究应关注丁丙诺啡贴剂对更具侵入性或更疼痛操作的效果。
局限性
- 证据不足以确认短暂副作用上的微小差异能否证明在该情境下使用一种新的、大多未经检验的镇痛方法合理。
- 未来研究应关注丁丙诺啡贴剂对更具侵入性或更疼痛操作的效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Appropriate analgesic protocols for patients following arthroscopic rotator cuff repair remain controversial. Although transdermal buprenorphine patches might potentially provide better pain control and fewer side effects, it is worth noting that there is limited evidence for this given a lack of direct comparisons with oral pain regimens. QUESTIONS/PURPOSES: Among patients undergoing arthroscopic rotator cuff repair, and compared with an analgesic approach using oral tramadol plus celecoxib: (1) Does perioperative use of buprenorphine patches provide better pain relief by a clinically important margin? (2) Does perioperative use of buprenorphine patches improve shoulder joint function recovery? (3) Does perioperative use of buprenorphine patches have a lower frequency of adverse reactions? METHODS: This was a prospective, single-center, randomized controlled trial. We included patients who underwent arthroscopic rotator cuff repair for partial- or full-thickness rotator cuff tears < 3 cm in size in the anterior to posterior direction as estimated by preoperative MRI and excluded those who had obesity, were pregnant, had opioid dependence, had history of cardiac bypass surgery or ipsilateral rotator cuff repair, had allergies to trial medications, were taking anticoagulants or antidepressants, were being treated with other postsurgical pain management methods, or had severe liver or kidney dysfunction. Based on these criteria, 64% (72 of 112) of patients were eligible. The patients were randomly assigned into either the control group (oral tramadol and celecoxib) or the experimental group (buprenorphine patches). The control group received 100 mg of tramadol and 200 mg of celecoxib every 12 hours for 2 weeks after surgery. The experimental group received buprenorphine patches about 48 hours before surgery without any oral medication. A medication journal was given to the patients to self-report their compliance in taking the drugs. The dosage regimen adhered strictly to protocol. After enrollment, 11% (4 of 36) of patients in the control group and 17% (6 of 36) of patients in the experimental group could not be fully analyzed because of loss to follow-up or missing data. The surveillance period was 3 months, and there was no crossover between groups. The groups did not differ at baseline in terms of demographic parameters and relevant clinical characteristics, including age, gender, BMI, American Society of Anesthesiologists classification, tear size, concomitant procedures, and number of anchors. The outcomes were (1) numeric rating scale (NRS) for pain score at rest or with movement, which ranges from 0 to 10, where 0 indicates no pain, and 10 indicates the worst pain; (2) the American Shoulder and Elbow Surgeons (ASES) score for joint function, which ranges from 0 to 100, with higher scores indicating better shoulder joint function; and (3) the incidence of postoperative adverse reactions. We defined the minimum clinically important difference on the NRS as 2 of 10 points and on the ASES score as 15 of 100 points, based on anchor-based approaches reported in other studies. RESULTS: We found no clinically important between-group differences in NRS pain scores at any time point, either at rest or with movement. Likewise, we found no clinically important between-group differences in ASES scores at any time point. Postoperative dizziness or drowsiness (20% [6 of 30 patients] versus 44% [14 of 32 patients]; p = 0.04) and nausea (10% [3 of 30 patients] versus 34% [11 of 32 patients]; p = 0.02) during the hospital stay were slightly lower in the experimental group compared with the control group. CONCLUSION: In this randomized trial, we found no clinically important advantages in pain or function to the use of buprenorphine patches after arthroscopic rotator cuff repair, and insufficient evidence exists to confirm whether the minor differences in transient side effects could justify the use of a new and largely untested analgesic approach in this context. That being so, we recommend against the routine use of buprenorphine patches for this indication. In general, we found that pain levels were low after the procedure in both groups. Future studies, therefore, should focus on the efficacy of buprenorphine patches for more invasive or more painful procedures. LEVEL OF EVIDENCE: Level I, therapeutic study.
引用
- Liu W, Qin J, Fang X, et al. Is the Use of a Buprenorphine Transdermal Patch More Effective Than Oral Medications for Postoperative Analgesia After Arthroscopic Rotator Cuff Repair? A Randomized Clinical Trial. Clin Orthop Relat Res. 2024. PMID: 39499769. doi:10.1097/CORR.0000000000003303
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。